Compare · GILD vs VCEL
GILD vs VCEL
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Vericel Corporation (VCEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and VCEL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $158.39B, about 90.0x VCEL ($1.76B).
- Over the past year, GILD is up 17.9% and VCEL is down 16.5% - GILD leads by 34.4 points.
- GILD has been more active in the news (21 items in the past 4 weeks vs 4 for VCEL).
- GILD has more recent analyst coverage (25 ratings vs 11 for VCEL).
- Company
- Gilead Sciences Inc.
- Vericel Corporation
- Price
- $129.01+1.15%
- $34.72+0.84%
- Market cap
- $158.39B
- $1.76B
- 1M return
- -2.80%
- -4.80%
- 1Y return
- +17.90%
- -16.46%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 21
- 4
- Recent ratings
- 25
- 11
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Latest GILD
- Chairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)
- Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
- New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
- FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC
- FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC
- Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
Latest VCEL
- The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
- Vericel Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Director Mclaughlin Kevin F exercised 7,000 shares at a strike of $7.84 and sold $229,775 worth of shares (7,000 units at $32.83) as part of a pre-agreed trading plan (SEC Form 4)
- Director Wotton Paul K sold $327,425 worth of shares (10,000 units at $32.74), decreasing direct ownership by 35% to 18,802 units (SEC Form 4)
- Chief Financial Officer Mara Joseph Anthony Jr sold $202,500 worth of shares (5,000 units at $40.50) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 21,009 units (SEC Form 4)
- Principal Accounting Officer Siegal Jonathan sold $188,045 worth of shares (4,855 units at $38.73) as part of a pre-agreed trading plan, decreasing direct ownership by 81% to 1,118 units (SEC Form 4)
- SEC Form 10-Q filed by Vericel Corporation
- Vericel Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
- Director Wotton Paul K converted options into 3,200 shares, increasing direct ownership by 12% to 28,802 units (SEC Form 4)